EX long-acting preparation can reduce weight, but there are few related clinical studies, and most focus on patients with T2DM
Chris Serres can be reached at [email protected]
It showed that the relative risks for aspiration, aspiration pneumonia, pneumonia, or respiratory failure were not elevated in patients prescribed GLP-1 RA compared to those receiving dipeptidylpeptidase-4 (DPP-4) inhibitors [21]
Cardiovascular benefits The SELECT trial a landmark cardiovascular outcomes study involving over 17,000 participants showed that semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with obesity who did not have diabetes
Their other product, resG, targets different pathways
A survey that included more than 8,000 GLP-1 users found that 15% had tried or were currently microdosing the drug